BMC
Medical Genomics

Open Access

Measurement of absolute copy number variation reveals association with essential hypertension

Francine Z Marques[1], Priscilla R Prestes[1], Leonardo B Pinheiro[2], Katrina Scurrah[3], Kerry R Emslie[2], Maciej Tomaszewski[4], Stephen B Harrap[3] and Fadi J Charchar[1*]

Abstract

Background: The role of copy number variation (CNV) has been poorly explored in essential hypertension in part due to technical difficulties in accurately assessing absolute numbers of DNA copies. Droplet digital PCR (ddPCR) provides a powerful new approach to CNV quantitation. The aim of our study was to investigate whether CNVs located in regions previously associated with blood pressure (BP) variation in genome-wide association studies (GWAS) were associated with essential hypertension by the use of ddPCR.

Methods: Using a "power of extreme" approach, we quantified nucleic acids using ddPCR in white subjects from the Victorian Family Heart Study with extremely high (n = 96) and low (n = 92) SBP, providing power equivalent to 1714 subjects selected at random.

Results: A deletion of the CNVs esv27061 and esv2757747 on chromosome 1p13.2 was significantly more prevalent in extreme high BP subjects after adjustment for age, body mass index and sex (12.6% vs. 2.2%; *P* = 0.013).

Conclusions: Our data suggests that CNVs within regions identified in previous GWAS may play a role in human essential hypertension.

Keywords: Copy number variation, Blood pressure, Hypertension, Extreme phenotypes, Droplet digital PCR

Background

Essential hypertension is a multifactorial condition with a substantial contribution attributed to heritable genetic factors [1]. Unravelling the genetic predisposition to high blood pressure (BP), however, has proven challenging, mostly due to phenotypic heterogeneity [2]. Single nucleotide polymorphisms (SNPs) have been the most studied type of polymorphism in essential hypertension, particularly in genome-wide association (GWA) studies [2]. A meta-analysis of GWA studies in 200,000 individuals of European ancestry found that 29 SNPs at 28 loci were associated with changes in systolic blood pressure (SBP), diastolic blood pressure (DBP) and/or hypertension [3]. A majority of these SNPs, however, are not causal being mere proxies of genuinely functional alleles in the vicinity.

In contrast to SNPs, copy number variations (CNVs) are large polymorphisms such as insertions, deletions, translocations and inversions of genomic material varying from 1 kilobase to several megabases [4,5]. CNVs cover about 12% of the human genome [6] and importantly, half of them overlap with protein-coding regions [7]. In humans 85–95% of CNVs are associated with changes in expression of the affected genes [8]. There have been very few studies on the association between CNVs and essential hypertension [3,9]. One reason for this paucity of data is that most of the techniques available up to now, such as real-time quantitative PCR (qPCR) [10], have proven unreliable, as they do not measure the absolute number of copies, a prerequisite for meaningful analyses of association between CNVs and BP variation.

The combined use of limited dilutions, Poisson distribution and PCR was first described in 1992 [11], allowing the measurement of the absolute numbers of nucleic acid in a sample, later called digital PCR (dPCR) [12]. In this study, we took advantage of a new system for dPCR analysis, the droplet digital PCR (ddPCR) [13]. High precision in copy number measurements can be achieved due to the large number of droplets analysed (>10,000)

* Correspondence: f.charchar@federation.edu.au
[1]Faculty of Science, Federation University Australia, Y Building, University Drive, Mt Helen, 3350, Ballarat, VIC, Australia
Full list of author information is available at the end of the article

for each sample [13]. The use of dPCR to measure CNVs is more reliable and precise compared to other techniques available [14,15].

The hypothesis of our study is that changes in genomic copy number may be associated with essential hypertension and/or BP variation but may have been missed in previous studies [9]. We first identified all the CNVs located in regions associated with BP/hypertension in the previous GWA meta-analysis. We then quantified these CNVs by high fidelity ddPCR to determine whether they are associated with hypertension. As a robust approach, we used the 'power of extreme' approach method [16,17] to enrich for rare but potent variants that could explain high BP.

Methods

Participants

The participants included in this study were selected from the Victorian Family Heart Study (VFHS), a healthy population-based cohort of European-descendants collected in Melbourne, Australia, to specifically study the family patterns in cardiovascular risk factors [18-21]. SBP was estimated based in the average of 2 lying SBP values and 2 standing SBP values. SBP and DBP for subjects on antihypertensive treatment (53.1% of the high BP group) were adjusted. Briefly, 10 mm Hg was added to systolic blood pressure and 5 mm Hg to diastolic blood pressure, as previously described [22,23]. In order to maximize the statistical power and enrich for rare variants in the current analysis, we selected a sex-matched sample of biologically unrelated subjects. We selected 96 and 92 subjects from the highest and lowest deciles for SBP in the VFHS, respectively. This was done in consideration of a mean SBP (122 mm Hg; SD: 14.3 mm Hg) in the VFHS, the mean SBPs of the high (166 mm Hg; SD: 12.3 mm Hg) and low (98 mm Hg; SD: 5.2 mm Hg) groups differed by ≈ 4.5 SDs. This provides power equivalent to 1714 subjects selected at random [22]. DNA was extracted from white blood cells. All subjects gave informed consent and the study was approved by the human research ethics committee at the Alfred Hospital, Melbourne, Australia.

In order to investigate whether having differential number of copies would lead to differential gene expression, we also genotyped forty Polish individuals of white European ancestry from the Silesian Renal Tissue Bank (SRTB), collected to study genetic aspects of human cardiovascular disease. DNA samples were extracted from white blood cells. Recruitment and phenotyping were as described [24,25]. Diagnosis of hypertension was as stipulated for the Silesian Hypertension Study. These subjects underwent elective unilateral nephrectomy because of non-invasive renal cancer. Samples from a pole of kidney unaffected by the neoplastic process had RNA extracted for gene expression analyses. All subjects gave informed consent and the study was approved by the human research ethics committee at the Medical University of Silesia, Poland.

Selection of copy number variation polymorphisms

We evaluated all top genomic regions associated to blood pressure phenotypes in the meta-analysis of GWA studies by Ehret et al., [3] to see whether these regions contain CNVs defined by the Database for Genomic Variation (DGV, http://dgv.tcag.ca/dgv/app/home) [26], to which both HapMap Project and 1000 Genomes Project are linked (Additional file 1: Figure S1). This screening retrieved 4 locations with CNV loci (Table 1). Two of the locations contained overlapping CNVs: esv27061 and esv2757747, and dgv976e1, esv2656635, nsv908562 and dgv986e1 (Table 1).

Droplet digital polymerase chain reaction (ddPCR)

This study followed the Minimum Information for Publication of Quantitative Digital PCR Experiments guidelines [27]. Four CNV assays were selected to genotype the 8 CNVs (Table 1). DNA samples, previously extracted from whole blood [18-21], were quantified by spectrophotometry. Given that one haploid human genome weighs 3.3 pg, and approximately 10,000 copies of genome per reaction are required for accurate ddPCR, we aimed to use 33 ng of DNA per reaction. Prior to PCR, DNA was restriction digested with either *XbaI*, *EcoRI* or *EcoRV* (Promega, Madison, Wisconsin, USA, 1 unit per 1 μg of DNA) for 1 hour at 37°C, followed by 20 minutes of heat inactivation at 65°C in a PCR thermal cycler (BioRad, Hercules, California, USA). PCR reactions were run in a total of 20 μl, containing 1 μl of the TaqMan assay (Life Technologies, Pleasanton, California, USA) specific for the CNV of interest, labelled with FAM dye, 1 μl of the copy number reference assay for the TaqMan® Copy Number Reference Assay

Table 1 Single nucleotide polymorphisms associated with high blood pressure located in regions containing copy number variation (Build hg19, based on the Database for Genomic Variants and UCSC Genome Browser, search performed on 28 May 2014)

SNP ID	CNV ID	Genomic landmark	Assay ID
rs2932538	esv27061	chr1:112,692,629-113,246,263	Hs01327571
	esv2757747*	chr1:113,157,135-116,741,372	Hs01327571
rs7129220	nsv483076	chr11:10,193,294-10,352,897	Hs04399968
rs17608766	dgv976e1	chr17:44,083,914-45,277,333	Hs00313538
	esv2656635	chr17:44,281,452-45,168,501	Hs00313538
	nsv908562	chr17:44,828,931-45,102,413	Hs00313538
	dgv986e1	chr17:44,971,360-45,277,333	Hs00313538
rs1327235	dgv1306e1	chr20:10,892,138-11,116,725	Hs03126928

Footnote: SNP, single nucleotide polymorphism; ID, identification; CNV, copy number variation.
*essv21692 is described in the UCSC Genome Browser, however, it is a supporting structural variant as a single individual. Therefore, according to NCBI, essv21962 is a part of the CNV esv2757747.

RNaseP (87 bp, Life Technologies, Pleasanton, California, USA), labelled with VIC dye, and 10 μl of the ddPCR™ Supermix for Probes (BioRad, Hercules, California, USA). Cycling conditions were: initial 1 x 95°C for 10 min, followed by 45 cycles of denaturation for 15 sec (ramp rate at 2.5°C per sec), annealing-extension for 60 sec (ramp rate at 2.5°C per sec), and finished with a heat kill at 98°C for 10 min. Denaturation and annealing-extension temperature were optimised for each assay to improve distinction between positive and negative droplets (Additional file 1: Table S1). Droplets were generated in a QX100 droplet generator (BioRad, Hercules, California, USA). PCR was run in a C1000 Touch PCR thermal cycler (BioRad, Hercules, California, USA), and the results were read in a QX100 droplet reader (BioRad, Hercules, California, USA). In order to confirm the genotypes, 29 to 67% (depending on the assay) of the samples were randomly repeated at least twice in independent experiments.

Data analyses

ddPCR data were analysed using the QuantaSoft software version 1.3.1.0, which measured the fraction of positive droplets and calculated the amount of template per droplet based on a Poisson distribution, which precision estimates a 95% confidence interval (CI) for each droplet. Agreement with normal distribution was assessed by histograms and estimation of skewness and kurtosis tests. A logistic regression adjusting for age, BMI and sex was performed to test the association between the CNVs and the extreme high and low BP groups. Independent-sample (two-tailed) Wilcoxon tests were used to identify if losses or gains of CNVs were associated with SBP or DBP in each group. Due to the small sample size, we did not adjust Wilcoxon tests by age, sex or BMI. The CNVs nsv483076, dgv976e1, esv2656635, nsv908562 and dgv986e1 were mostly monomorphic, so no statistical analyses were performed. Differences with $P < 0.05$ were considered statistically significant. Statistical package SPSS for Windows (Release 17.0, 2008) was used in the statistical analysis.

Results

Mean SBP, DBP, age and BMI values were significantly higher in extreme high when compared to low BP groups (Table 2) [22]. The mean number of droplets analysed (±standard error of measurement) for all the samples ranged between 12729 ± 98 and 14725 ± 122 droplets, depending on the assay. Samples in which number of copies did not fall within the 95% Poisson CI for absolute number of 1, 2 or 3 copies per diploid genome, and samples that failed to amplify were repeated at least twice with consistent results, and therefore were excluded from further analyses. One sample was excluded for CNVs esv27061 and esv2757747 (0.5%), 7 for CNV nsv483076 (3.7%), 2 for the CNVs dgv976e1, esv2656635, nsv908562 and dgv986e1

Table 2 Characteristics of the extreme low and high blood pressure subjects from the Victorian family heart study

Characteristic	Extreme low BP (n = 92)	Extreme high BP (n = 96)	P-value
SBP	98.6 ± 5.2 mmHg	165.9 ± 12.3 mmHg	$P < 0.001$
DBP	64.3 ± 7.2 mmHg	94.4 ± 10.8 mmHg	$P < 0.001$
Age	32.6 ± 14.5 years old	55.1 ± 8.3 years old	$P < 0.001$
BMI	22.7 ± 3.2 kg.m^{-2}	28.3 ± 4.5 kg.m^{-2}	$P < 0.001$
Males (%)	47 (51.1%)	48 (50%)	$P = 0.88$

Footnote: BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index.
Values are represented are average ± standard deviation.

(1%) and 14 for CNV dgv1306e1 (7.4%). We observed between 5466 ± 244 and 7872 ± 369 copies of DNA, depending on the assay. There was a high concordance between replicates of the same sample (data not shown). Additional file 1: Figure S2 shows an example of the quality of the copy calls, reporting replicates with either 1, 2 or 3 copies.

There was a significantly higher prevalence of a deletion in the overlapping CNVs esv27061 and esv2757747 on chromosome 1 in individuals from extreme high BP (n = 12) than those from extreme low BP (n = 2) group (12.6% vs. 2.2%, respectively; 95% confidence interval: 0.005–0.53; β = 0.05; $P = 0.013$) after adjustment for BMI, age and sex (Table 3 and Additional file 1: Figure S3). Within the stratum of high extreme of SBP, there were no significant difference in either SBP (+3.65 mmHg, $P = 0.884$) or DBP (+0.53 mmHg, $P = 0.263$) between subjects with 1 or 2 copies of these CNVs (Figures 1A and B). In the extreme low BP group the increase was of greater magnitude (+6.03 mmHg SBP and 7.84 mmHg DBP), but the number of subjects with the deletion was very small to perform statistical analyses (n = 2).

Although there was no association between CNV dgv1306e1 on chromosome 20p12.2 and the extreme high and low BP (Additional file 1: Table S2), subjects from the extreme low BP group with 3 copies had higher, but non-significant, SBP (+2.4 mmHg, $P = 0.069$) and DBP (+3.5 mmHg, $P = 0.066$) (Figure 1C and D). Subjects from extreme high BP group with 3 copies of CNV dgv1306e1 had no significant difference in SBP (–4.5 mmHg, $P = 0.308$) than those with 2 copies, but they had significantly lower DBP (–5.5 mmHg, $P = 0.024$) (Figure 1E and F).

No association was observed between the phenotypes investigated and the CNV nsv483076 on chromosome 11p15.4, in which only one subject of the extreme high BP group presented a duplication (Table 3).

The frequencies of the CNVs found in this study were compared to the DGV data (Additional file 1: Table S2). We observed that the presence of CNVs in the studies described in the DGV was different from some of the ones found in the present study. There was no gain

Table 3 Copy number variation (CNV) frequency in the extreme low and high cohort

Number of copies	CNV esv27061/esv2757747*		CNV nsv483076		CNV dgv976e1/esv2656635/ nsv908562/dgv986e1	CNV dgv1306e1	
	1 copy (%)	2 copies (%)	2 copies (%)	3 copies (%)	2 copies (%)	2 copies (%)	3 copies (%)
Low BP: sample size (%)	2 (2.2)	90 (97.8)	90 (100)	0	91 (100)	63 (76.8)	19 (23.2)
High BP: sample size (%)	12 (12.6)	83 (87.4)	88 (98.9)	1 (1.1)	93 (100)	74 (82.2)	16 (17.8)

*$P = 0.013$ after adjustment for age, body mass index and sex.
Footnote: CNV, copy number variation; BP, blood pressure.

in number of copies in the CNVs esv27061 and esv2757747 for all participants we studied, while the reported prevalence of gain in the DGV is 5.8% and 0.8%, respectively (Additional file 1: Table S2). For the CNV dgv1306e1, we observed a higher prevalence of variation of 20.3%, while the DGV reports only no variance.

All subjects genotyped for the SRTB cohort had 2 copies of the CNVs esv27061 and esv2757747, and therefore, we could not investigate if there was a correlation between gene expression and the deletion of a copy number in this region (data not shown).


Figure 1 Systolic blood pressure (SBP) and diastolic blood pressure (DBP) according to the genotype of CNVs. According to the genotype for the CNVs esv27061 and esv2757747, there was no statistically significant difference in **(A)** SBP and **(B)** DBP in the extreme high blood pressure (BP) group. According to the genotype for the CNV dgv1306e1, there was no difference in **(C)** SBP and **(D)** DBP in the extreme low blood pressure group, while **(E)** there was a significant decrease in DBP in the extreme high BP group (* indicates $P = 0.024$), and **(F)** no change in SBP. Independent-sample Wilcoxon tests were performed between subjects with losses or gains in copy number in each BP group. Graphs represent mean, error bars represent standard deviation.

Discussion

This study is the first, to our knowledge, to investigate copy number variation in regions previously associated with BP in genome-wide association studies by the use of absolute DNA quantitation of droplet digital PCR and the 'power of extreme' approach. Significantly higher frequency of a deletion of the overlapping CNVs esv27061 and esv2757747 on chromosome 1 was observed in those with extreme high BP compared to low BP subjects. These CNVs are overlapping with the SNP rs2932538, which was previously associated with hypertension [3]. This indicates that CNVs in this region could contribute to the previous positive association in the GWA meta-analysis. Although no association was observed between the other three regions studied, subjects from extreme high SBP with 3 copies of the CNV dgv1306e1 in chromosome 20 had significantly lower DBP. Surprisingly, the frequency of copy number in our cohort of 184 European-descendent subjects was very different than the one in the DGV, which suggests that the data available in this database might be biased due to less reliable measurement techniques.

Although we reported here that a deletion of the CNVs esv27061 and esv2757747 was more prevalent in hypertensive subjects, we could not find a significant association with BP. This is likely a consequence of the sampling design employed in this study. The selection of subjects with extreme high and extreme low from a population-based sample such as the VFHS offers power in terms of the comparisons between, but not necessarily within the extreme groups. Factors such as low prevalence of certain variants and high standard deviation in the extreme high group militate against detection of effects within groups. Nevertheless, the observed BP differences with the deletion of the CNVs esv27061 and esv2757747 were of consistent direction in both high and low extreme groups. Also our data is consistent with the GWA meta-analysis, in which the loci containing SNP rs2932538 and CNVs esv27061/esv2757747 on chromosome 1 was associated with hypertension, but had a small effect ($\beta = 0.049$) [3], very comparable to our result ($\beta = 0.05$). Other parallels between our CNV data and the GWA meta-analysis were observed for the CNV dgv1306e1, which showed a stronger association between the SNP rs1327235 in chromosome 20 (where the CNV dgv1306e1 is located) and DBP ($P = 1.4 \times 10^{-15}$) than SBP ($P = 1.9 \times 10^{-8}$) or hypertension ($P = 4.6 \times 10^{-4}$) [3].

The CNV esv2757747, located on 1p13.2-1p13.1, is approximately 3.5 megabase pairs long (Mb) and encompasses 45 coding genes, including the one previously associated with BP coding moloney leukemia virus 10 (*MOV10*) [3], and several genes for long non-coding RNAs (lncRNAs) of unknown function, but expressed in relevant tissues such as heart and kidney (Additional file 1: Table S3). LncRNAs, important for epigenetic regulation, are emerging as a new class of non-coding RNAs possibly involved in cardiovascular disease [28]. Amongst the genes in this region is the one coding for the nerve growth factor (*NGF*). This gene been previously implicated in BP regulation in the spontaneously hypertensive rats (SHR), the most studied model of hypertension [29,30].

The esv27061 variant is a smaller CNV of 553,635 bp on chromosome 1p13.2, which encompass 9 genes, including *MOV10,* and a gene for a microRNA, miR-4256 (Additional file 1: Table S3). Besides *MOV10*, none of them have been previously associated with BP or hypertension. The CNV dgv1306e1, of 224,588 bp on 20p12.2, initially contained the jagged 1 gene (*JAG1*) when the meta-analysis was published [3]. In the newest human genome browser, GRCh37/hg19, *JAG1* no longer maps within CNV dgv1306e1, while one new transcript (*C20orf187*) and several new lncRNAs, with unknown roles but transcribed in relevant tissues to BP regulation such as kidney, have been described in this region (Additional file 1: Table S3).

The combined usage of comparative genomic hybridisation (CGH) arrays and qPCR identified 16 CNVs associated with BP distributed across 8 chromosomes in the SHR [31]. The expression of several genes within theses CNVs were validated in kidney, heart and spleen [31]. Of particular interest was the gene coding for EGL nine homolog 1 (*Egln1*), which is located in an orthologous region in humans and was shown in a large F_2 cross to be associated with BP [31]. No validation, however, has been done in humans so far. A study which sequenced the whole-genome of the SHR identified 588 CNVs overlapping with 688 genes [32], but gene expression was not investigated. There are few studies aimed at finding CNVs that could contribute to the pathophysiology of essential hypertension in humans. The first GWA study for CNVs in essential hypertension, which designed their own arrays using the Agilent CGH platform, analysed ~2,000 hypertensive subjects with British ancestry and ~3,000 controls, and found no association between any CNVs and hypertension [9]. Interestingly, from the initial 11,541 loci targeted, only 3,432 CNVs (31.6%) passed quality control filters indicating the difficulty in accurate quantitation. Another study which used a similar population size converted data from SNP-arrays to CNVs based on allele intensity, and found 7 CNVs associated with hypertension [33]. None of these regions, however, are the same ones identified in this study or in the GWA meta-analysis [3].

In order to find the functional role for the CNVs associated with hypertension in this study, we genotyped 40 Polish subjects with normal or high BP, for which we have matching kidney samples. All subjects, however, had 2 copies of the CNVs esv27061 and esv2757747, and therefore, we could not investigate if there was a correlation between gene expression and the deletion of a copy number in this region (data not shown). The lack of variability in

this population may be explained by the different genetic background of the two cohorts (white-Australian vs. Polish), the small sample size of the Polish cohort analysed, or by the enrichment for rare variants in the extreme BP groups [34].

The frequency of loss or gain of copy number described in the DGV (UCSC Genome Browser and GRCh37/hg19 assembly, search performed on 29 May 2014) is presented in Additional file 1: Table S2 [4,6,35]. For the CNVs esv27061 and esv2757747, we did not observe any gain in copy number for all subjects genotyped. Furthermore, the higher prevalence of the CNV dgv1306e1 in our cohort (20.3%) compared to the DGV (0%) could be a result of the enrichment for rare variants by the use of the 'power of extreme' approach for high and low BP used in the present study [34], or high diversity between different populations for this and CNV dgv1306e1 loci. The studies that reported these first frequencies, however, used CGH arrays and small sample sizes (n = 40, [4] n = 55 [4] and n = 270 [6]) compared to more recent whole-genome studies. CGH arrays are based on hybridisation of labelled DNA to genomic clones, together with the hybridisation of a reference sample; therefore it is a relative measurement. Literature suggests <70% reproducibility in replicate experiments between platforms and algorithms for CGH and SNP arrays used for CNV detection [36]. The 1000 Genomes Project, which used a combination of exome sequencing and low-coverage whole-genome [37], will hopefully be able to rectify the frequency of CNVs reported in databases.

Technical difficulties and inaccuracy have been reported in the measurement of CNVs by qPCR [10]. For single CNV investigations, studies comparing qPCR and dPCR have proven the superiority of dPCR in accuracy and reproducibility [14,15]. One of the reasons is the number of replicates necessary for accurate qPCR results. For example, at least 8 replicates are needed when using qPCR to detect ratios of relative quantity greater than 1.25 with 95% power [15]. Some samples were excluded because an absolute 1, 2 or 3 copy number (0.5-7.4% depending on the assay) was not obtained. This may be caused by mosaicism in the population, in accordance with recent findings by another group using ddPCR [38], or degradation of this region in some DNA copies.

We have to acknowledge several limitations of the present study. One limitation relates to the absence of a clear agreement regarding quality control for results obtained by the new technology of ddPCR. The technique is labour intensive and each sample needs to be analysed individually. The small sample sizes would normally limit power for detection of genetic association. However, the use of the extreme phenotype approach enhances the power to detect association [16,17,22,39,40]. Previous calculations [39] of our effective sample size estimated power

to be equivalent to an analysis of 1714 unselected subjects [20]. One consideration about the use of extreme phenotypes, however, is that it could select for rare syndromes and associated diseases, therefore decreasing the physiological relevance of the associations. To minimise this possible issue, subjects with other forms of hypertension than essential hypertension were excluded increasing the genetic power of our analyses. Finally, we did not validate the findings in a larger population because these regions have been previously associated with BP and hypertension in over 200,000 subjects [3].

Conclusions

Our results show an association between the CNVs esv27061 and esv2757747 and extreme high BP subjects, and the CNV dgv1306e1 and DBP in hypertensive subjects by the use of the recently available and highly precise ddPCR in an extreme phenotype study. The results are in accordance to largest GWA meta-analysis, and together they suggest that CNVs in at least one of these regions could be an underlying factor to the initial association. The function of these CNVs in BP regulation, however, needs to be clarified.

Additional file

Additional file 1: Online Data Supplement.

Author details
[1]Faculty of Science, Federation University Australia, Y Building, University Drive, Mt Helen, 3350, Ballarat, VIC, Australia. [2]National Measurement Institute, Sydney, NSW, Australia. [3]Department of Physiology, University of Melbourne, Melbourne, VIC, Australia. [4]Department of Cardiovascular Science, University of Leicester, Leicester, UK.

References
1. Charchar F, Zimmerli L, Tomaszewski M: **The pressure of finding human hypertension genes: new tools, old dilemmas.** *J Hum Hypertens* 2008, **22**(12):821–828.
2. Munroe PB, Barnes MR, Caulfield MJ: **Advances in blood pressure genomics.** *Circ Res* 2013, **112**(10):1365–1379.
3. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, O'Reilly PF, Amin N, Bragg-Gresham JL, Teumer A, Glazer NL, Launer L, Zhao JH, Aulchenko Y, Heath S, Sober S, Parsa A, Luan J, Arora P, Dehghan A, Zhang F, Lucas G, Hicks AA, Jackson AU, *et al*: **Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk.** *Nature* 2011, **478**(7367):103–109.
4. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, Lee C: **Detection of large-scale variation in the human genome.** *Nat Genet* 2004, **36**(9):949–951.
5. Sharp AJ, Locke DP, McGrath SD, Cheng Z, Bailey JA, Vallente RU, Pertz LM, Clark RA, Schwartz S, Segraves R, Oseroff VV, Albertson DG, Pinkel D, Eichler EE: **Segmental duplications and copy-number variation in the human genome.** *Am J Hum Genet* 2005, **77**(1):78–88.
6. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson AR, Chen W, Cho EK, Dallaire S, Freeman JL, Gonzalez JR, Gratacos M, Huang J, Kalaitzopoulos D, Komura D, MacDonald JR, Marshall CR, Mei R, Montgomery L, Nishimura K, Okamura K, Shen F, Somerville MJ, Tchinda J, Valsesia A, Woodwark C, Yang F, *et al*: **Global variation in copy number in the human genome.** *Nature* 2006, **444**(7118):444–454.
7. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S, Massa H, Walker M, Chi M, Navin N, Lucito R, Healy J, Hicks J, Ye K, Reiner A, Gilliam TC, Trask B, Patterson N, Zetterberg A, Wigler M: **Large-scale copy number polymorphism in the human genome.** *Science* 2004, **305**(5683):525–528.
8. Feuk L, Carson AR, Scherer SW: **Structural variation in the human genome.** *Nat Rev Genet* 2006, **7**(2):85–97.
9. Craddock N, Hurles ME, Cardin N, Pearson RD, Plagnol V, Robson S, Vukcevic D, Barnes C, Conrad DF, Giannoulatou E, Holmes C, Marchini JL, Stirrups K, Tobin MD, Wain LV, Yau C, Aerts J, Ahmad T, Andrews TD, Arbury H, Attwood A, Auton A, Ball SG, Balmforth AJ, Barrett JC, Barroso I, Barton A, Bennett AJ, Bhaskar S, Blaszczyk K: **Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls.** *Nature* 2010, **464**(7289):713–720.
10. Aldhous MC, Abu Bakar S, Prescott NJ, Palla R, Soo K, Mansfield JC, Mathew CG, Satsangi J, Armour JA: **Measurement methods and accuracy in copy number variation: failure to replicate associations of β-defensin copy number with Crohn's disease.** *Hum Mol Genet* 2010, **19**(24):4930–4938.
11. Sykes PJ, Neoh SH, Brisco MJ, Hughes E, Condon J, Morley AA: **Quantitation of targets for PCR by use of limiting dilution.** *Biotechniques* 1992, **13**(3):444–449.
12. Vogelstein B, Kinzler KW: **Digital PCR.** *Proc Natl Acad Sci U S A* 1999, **96**(16):9236–9241.
13. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ, Bright IJ, Lucero MY, Hiddessen AL, Legler TC, Kitano TK, Hodel MR, Petersen JF, Wyatt PW, Steenblock ER, Shah PH, Bousse LJ, Troup CB, Mellen JC, Wittmann DK, Erndt NG, Cauley TH, Koehler RT, So AP, Dube S, Rose KA, Montesclaros L, Wang S, Stumbo DP, Hodges SP: **High-throughput droplet digital PCR system for absolute quantitation of DNA copy number.** *Anal Chem* 2011, **83**(22):8604–8610.
14. Weaver S, Dube S, Mir A, Qin J, Sun G, Ramakrishnan R, Jones RC, Livak KJ: **Taking qPCR to a higher level: analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution.** *Methods* 2010, **50**(4):271–276.
15. Whale AS, Huggett JF, Cowen S, Speirs V, Shaw J, Ellison S, Foy CA, Scott DJ: **Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation.** *Nucleic Acids Res* 2012, **40**(11):e82.
16. Froguel P, Blakemore AI: **The power of the extreme in elucidating obesity.** *N Engl J Med* 2008, **359**(9):891–893.
17. Walters RG, Jacquemont S, Valsesia A, De Smith AJ, Martinet D, Andersson J, Falchi M, Chen F, Andrieux J, Lobbens S, Delobel B, Stutzmann F, El-Sayed Moustafa JS, Chevre JC, Lecoeur C, Vatin V, Bouquillon S, Buxton JL, Boute O, Holder-Espinasse M, Cuisset JM, Lemaitre MP, Ambresin AE, Brioschi A, Gaillard M, Giusti V, Fellmann F, Ferrarini A, Hadjikhani N, Campion D, *et al*: **A new highly penetrant form of obesity due to deletions on chromosome 16p11.2.** *Nature* 2010, **463**(7281):671–675.
18. Harrap SB, Wong ZY, Stebbing M, Lamantia A, Bahlo M: **Blood pressure QTLs identified by genome-wide linkage analysis and dependence on associated phenotypes.** *Physiol Genomics* 2002, **8**(2):99–105.
19. Ellis JA, Stebbing M, Harrap SB: **Male pattern baldness is not associated with established cardiovascular risk factors in the general population.** *Clin Sci (Lond)* 2001, **100**(4):401–404.
20. Ellis JA, Wong ZY, Stebbing M, Harrap SB: **Sex, genes and blood pressure.** *Clin Exp Pharmacol Physiol* 2001, **28**(12):1053–1055.
21. Harrap SB, Stebbing M, Hopper JL, Hoang HN, Giles GG: **Familial patterns of covariation for cardiovascular risk factors in adults: the Victorian Family Heart Study.** *Am J Epidemiol* 2000, **152**(8):704–715.
22. Busst CJ, Scurrah KJ, Ellis JA, Harrap SB: **Selective genotyping reveals association between the epithelial sodium channel γ-subunit and systolic blood pressure.** *Hypertension* 2007, **50**(4):672–678.
23. Vincent M, Boussairi EH, Cartier R, Lo M, Sassolas A, Cerutti C, Barres C, Gustin MP, Cuisinaud G, Samani NJ: **High blood pressure and metabolic disorders are associated in the Lyon hypertensive rat.** *J Hypertens* 1993, **11**(11):1179–1185.
24. Tomaszewski M, Charchar FJ, Nelson CP, Barnes T, Denniff M, Kaiser M, Debiec R, Christofidou P, Rafelt S, van der Harst P, Wang WY, Maric C, Zukowska-Szczechowska E, Samani NJ: **Pathway analysis shows association between FGFBP1 and hypertension.** *J Am Soc Nephrol* 2011, **22**(5):947–955.
25. Marques FZ, Campain AE, Tomaszewski M, Yang YHJ, Zukowska-Sczechowska E, Charchar FJ, Morris BJ: **Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs.** *Hypertension* 2011, **58**:1093–1098.
26. MacDonald JR, Ziman R, Yuen RK, Feuk L, Scherer SW: **The Database of Genomic Variants: a curated collection of structural variation in the human genome.** *Nucleic Acids Res* 2014, **42**(Database issue):D986–D992.
27. Huggett JF, Foy CA, Benes V, Emslie K, Garson JA, Haynes R, Hellemans J, Kubista M, Mueller RD, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT, Bustin SA: **The Digital MIQE Guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments.** *Clin Chem* 2013, **59**(6):892–902.
28. Schonrock N, Harvey RP, Mattick JS: **Long noncoding RNAs in cardiac development and pathophysiology.** *Circ Res* 2012, **111**(10):1349–1362.
29. Charchar FJ, Kapuscinski MK, Harrap SB: **Nerve growth factor gene locus explains elevated renal nerve growth factor mRNA in young spontaneously hypertensive rats.** *Hypertension* 1998, **32**(4):705–709.
30. Nemoto K, Sekimoto M, Fukamachi K, Kageyama H, Degawa M, Hamadai M, Hendley ED, Macrae IM, Clark JS, Dominiczak AF, Ueyama T: **No involvement of the nerve growth factor gene locus in hypertension in spontaneously hypertensive rats.** *Hypertens Res* 2005, **28**(2):155–163.
31. Charchar FJ, Kaiser M, Bingham AJ, Fotinatos N, Ahmady F, Tomaszewski M, Samani NJ: **Whole genome survey of copy number variation in the spontaneously hypertensive rat: relationship to quantitative trait loci, gene expression, and blood pressure.** *Hypertension* 2010, **55**(5):1231–1238.
32. Atanur SS, Birol I, Guryev V, Hirst M, Hummel O, Morrissey C, Behmoaras J, Fernandez-Suarez XM, Johnson MD, McLaren WM, Patone G, Petretto E, Plessy C, Rockland KS, Rockland C, Saar K, Zhao Y, Carninci P, Flicek P, Kurtz T, Cuppen E, Pravenec M, Hubner N, Jones SJ, Birney E, Aitman TJ: **The genome sequence of the spontaneously hypertensive rat: analysis and functional significance.** *Genome Res* 2010, **20**(6):791–803.
33. Chen X, Li X, Wang P, Liu Y, Zhang Z, Zhao G, Xu H, Zhu J, Qin X, Chen S, Hu L, Kong X: **Novel association strategy with copy number variation for identifying new risk loci of human diseases.** *PLoS One* 2010, **5**(8):e12185.
34. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS,

Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM: **Finding the missing heritability of complex diseases.** *Nature* 2009, **461**(7265):747–753.

35. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, Aerts J, Andrews TD, Barnes C, Campbell P, Fitzgerald T, Hu M, Ihm CH, Kristiansson K, Macarthur DG, Macdonald JR, Onyiah I, Pang AW, Robson S, Stirrups K, Valsesia A, Walter K, Wei J, Tyler-Smith C, Carter NP, Lee C, Scherer SW, Hurles ME: **Origins and functional impact of copy number variation in the human genome.** *Nature* 2010, **464**(7289):704–712.

36. Pinto D, Darvishi K, Shi X, Rajan D, Rigler D, Fitzgerald T, Lionel AC, Thiruvahindrapuram B, Macdonald JR, Mills R, Prasad A, Noonan K, Gribble S, Prigmore E, Donahoe PK, Smith RS, Park JH, Hurles ME, Carter NP, Lee C, Scherer SW, Feuk L: **Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants.** *Nat Biotechnol* 2011, **29**(6):512–520.

37. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA: **An integrated map of genetic variation from 1,092 human genomes.** *Nature* 2012, **491**(7422):56–65.

38. Abyzov A, Mariani J, Palejev D, Zhang Y, Haney MS, Tomasini L, Ferrandino AF, Rosenberg Belmaker LA, Szekely A, Wilson M, Kocabas A, Calixto NE, Grigorenko EL, Huttner A, Chawarska K, Weissman S, Urban AE, Gerstein M, Vaccarino FM: **Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells.** *Nature* 2012, **492**(7429):438–442.

39. Donner A, Klar N: *Design and analysis of cluster randomization trials in health research.* New York, NY: Oxford University Press; 2000.

40. Van Gestel S, Houwing-Duistermaat JJ, Adolfsson R, van Duijn CM, Van Broeckhoven C: **Power of selective genotyping in genetic association analyses of quantitative traits.** *Behav Genet* 2000, **30**(2):141–146.